Used in research and development for inflammatory and autoimmune diseases, this antibody targets CXCL10 (IP-10), a chemokine involved in recruiting immune cells to sites of inflammation. It is applied in preclinical studies to modulate immune responses, particularly in conditions like psoriasis, rheumatoid arthritis, and lupus. It also serves as a reference reagent in assay development, helping evaluate the potency and specificity of therapeutic candidates targeting the CXCL10 pathway. Additionally, it supports biomarker validation in clinical research, aiding in patient stratification and treatment monitoring.